Ravindra Kumar, Cambridge, MA (US); Asya Grinberg, Cambridge, MA (US); Dianne Sako, Cambridge, MA (US); Robert Scott Pearsall, Cambridge, MA (US); and Roselyne Castonguay, Cambridge, MA (US)
Assigned to ACCELERON PHARMA INC., Cambridge, MA (US)
Filed by Acceleron Pharma Inc., Cambridge, MA (US)
Filed on Feb. 8, 2022, as Appl. No. 17/666,705.
Application 16/158,661 is a division of application No. 15/092,573, filed on Apr. 6, 2016, granted, now 10,196,434, issued on Feb. 5, 2019.
Application 17/666,705 is a continuation of application No. 16/803,230, filed on Feb. 27, 2020, granted, now 11,279,746.
Application 16/803,230 is a continuation of application No. 16/158,661, filed on Oct. 12, 2018, granted, now 10,738,098, issued on Aug. 11, 2020.
Claims priority of provisional application 62/220,836, filed on Sep. 18, 2015.
Claims priority of provisional application 62/143,579, filed on Apr. 6, 2015.
Prior Publication US 2022/0242927 A1, Aug. 4, 2022
1. A method for treating kidney fibrosis and/or kidney inflammation, comprising administering to a patient in need thereof an effective amount of a recombinant ALK4:ActRIIB heteromultimer comprising an ALK4 polypeptide and an ActRIIB polypeptide, wherein the ALK4 polypeptide comprises an amino acid sequence that is at least 95% identical to amino acids 34-101 of SEQ ID NO: 9, and wherein the ActRIIB polypeptide comprises an amino acid sequence that is at least 95% identical to amino acids 29-109 of SEQ ID NO: 1, wherein the ALK4 polypeptide and/or the ActRIIB polypeptide is a fusion protein further comprising a heterologous domain, and wherein the heteromultimer binds to activin B.